Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer | Research To Practice

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer

September 15, 2019, Chicago, Illinois

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer

Please note that slides are for review only and not to be repurposed or published.

INTRODUCTION:
Dr Langer

MODULE 1:
Established Management Paradigms and Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors for Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Jolly

MODULE 2:
Integration of Immune Checkpoint Inhibition into the Management of Locally Advanced NSCLC — Dr Langer

MODULE 3:
Incidence, Recognition and Management of Immune-Mediated and Other Toxicities with the Use of Anti-PD-L1 Antibody Therapy for Locally Advanced Disease — Dr Patel

MODULE 4:
Ongoing and Planned Clinical Trials of Immune Checkpoint Inhibitors for Patients with Nonmetastatic NSCLC — Dr Loo

Live Poll Results
Download